3 lines
No EOL
1,015 B
Markdown
3 lines
No EOL
1,015 B
Markdown
```json
|
|
{"action": "flag_duplicate", "candidates": ["medicaid-glp1-coverage-reversing-through-state-budget-pressure.md", "glp-1-access-structure-inverts-need-creating-equity-paradox.md", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation.md"], "reasoning": "The claim 'California Medi-Cal's 2026 GLP-1 obesity coverage elimination demonstrates access inversion due to budget constraints' substantially overlaps with 'medicaid-glp1-coverage-reversing-through-state-budget-pressure.md' by discussing the same California policy, cost trajectory, and budget pressure. It also relates to 'glp-1-access-structure-inverts-need-creating-equity-paradox.md' by highlighting access inversion, and 'glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation.md' by implicitly linking the need for continuous treatment to the escalating costs and subsequent coverage elimination."}
|
|
``` |